Converge Bio
Last verified 2026-05-19. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $30.0Mattributed |
|---|---|
| Latest round | series-a, $25.0M, 2026-01-13attributed |
| Founded | 2024 |
| Headquarters | Boston, USA |
| Industry | bio |
| Stage | series-a |
| Website | converge-bio.com |
Converge Bio provides a generative AI platform that accelerates drug discovery, molecule design, and manufacturing optimization. It serves pharmaceutical and biotech teams shortening development cycles. Customer data stays private and is never shared or used for model training, keeping proprietary research under full customer control.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-13 | series-a | $25.0M | undisclosed |
Detected tech stack
Google Tag Manager, Framer Sites, HubSpot, Cookiebot, React 16.13.1, lottie-web 5.12.2
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $25.0M | attributed | techcrunch named as publisher. No document URL on file. |
| Total raised $30.0M | attributed | techcrunch named as publisher. No document URL on file. |
| Company existence | self-reported | converge-bio.com, read 2026-05-19 |
| Description | self-reported | converge-bio.com, read 2026-05-19 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.